Polarean Imaging’s Xenon MRI to Take Center Stage at ATS 2025

Polarean Imaging ( (GB:POLX) ) just unveiled an announcement.

Polarean Imaging plc’s Xenon MRI technology will be prominently featured at the American Thoracic Society’s 2025 Respiratory Innovation Summit and International Conference, highlighting its growing recognition as a pivotal tool in respiratory care. With over 30 presentations from leading clinical sites, the technology’s versatility across various respiratory conditions is showcased, reinforcing its role in both clinical care and trials. This presence underscores Polarean’s position at the forefront of respiratory medicine, as the company continues to engage with industry leaders and stakeholders to advance functional lung imaging.

The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.

More about Polarean Imaging

Polarean Imaging plc is a revenue-generating medical imaging technology company focused on revolutionizing pulmonary medicine through advanced MRI techniques. The company specializes in direct visualization of lung function, addressing the unmet medical needs of over 500 million patients with chronic respiratory diseases. Polarean is a leader in hyperpolarization science, offering the FDA-approved XENOVIEW®, a hyperpolarized Xenon MRI inhaled contrast agent, and is dedicated to developing non-invasive, radiation-free pulmonary functional MRI platforms.

Average Trading Volume: 2,414,358

Technical Sentiment Signal: Sell

Current Market Cap: £11.17M

See more insights into POLX stock on TipRanks’ Stock Analysis page.